Webinar presenter Raza Hoda, MD, Staff Pathologist, Cleveland Clinic, Assistant Professor of Pathology, Cleveland Clinic Lerner College of Medicine, discusses the importance of advancements in HER2 testing, including HER2 Ultra Low.
This on-demand webinar was originally broadcast on June 10, 2025.
What will you learn from this webinar?
• Review the role of HER2 in breast carcinoma, including its biological significance and impact on treatment decisions.
• Trace the evolution of HER2-targeted therapy and its influence on patient outcomes.
• Examine the progression of HER2 testing guidelines and their implications for clinical practice.
• Discuss HER2 Low, Ultralow, and Null categories, and interpret their emerging clinical relevance.
• Identify key diagnostic challenges in HER2 IHC interpretation and apply best practices to overcome them.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.